Rebecca Kaltman is an Oncology physician affiliated with Inova Health System. OpenAlex indexes 44 publications with 254 citations (h-index 8); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
8081 Innovation Park Dr
Fairfax, VA 220314867
Telephone
571-472-4724Provider last certified this registry record 15 Dec 2021.
Clinical trials
- Burn Pit Exposure in Veterans: A Cancer Screening Pilot Study at the Inova Saville Cancer Screening & Prevention Center
Sponsor: Inova Health Care Services
- Occupational Cancer Screening in Firefighters: A Pilot Study Within the Inova Health System
Sponsor: Inova Health Care Services
- Assessing the Sensitivity of "SureTouch™" in Women Undergoing Diagnostic and Screening Mammography
Sponsor: George Washington University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Myriad Genetic Laboratories, Inc.Program year20241 payment
- Gilead Sciences, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Hormonal (systemic)
100%l-Thyroxine100%Levothyroxine Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2024–2026 per NIH RePORTER. The latest:
- Virginia Cancer Screening Research Network Access Hub (Virginia CSRN Hub)
Virginia Commonwealth University
FY2026$1,419,262UG1CA287017 - Virginia Cancer Screening Research Network Access Hub (Virginia CSRN Hub)
Virginia Commonwealth University
FY2025$806,066UG1CA287017 - Virginia Cancer Screening Research Network Access Hub (Virginia CSRN Hub)
Virginia Commonwealth University
FY2025$502,745UG1CA287017
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
William Ershler, MD
Inova Health System
Wayne Batchelor, MD
Inova Health System
Mitchell Psotka, MD, PhD
Inova Health System
Brett Atwater, MD
Inova Health System
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”